# Corcept Therapeutics Inc. (CORT)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001088856 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001088856))
- Full page: https://inspectstocks.com/stocks/cort
- Data as of: price 2026-09-25; newest filing used 2026-07-29; latest fiscal period ended 2026-06-30

## Grade

**C** on the growth-and-cash rubric, 3 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Revenue growing overall | passed | $830.8M | $428.2M |
| Revenue growing recently | passed | $830.8M | $761.4M |
| Free cash flow positive | passed | $106.9M |  |
| Free cash flow growing overall | failed | $106.9M | $134.8M |
| Free cash flow growing recently | failed | $106.9M | $141.8M |

Business quality (the + / − mark): 3 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | passed | 6.6% |  |
| Healthy profit margin | failed | 6.6% |  |
| Strong operating margin | failed | 0.8% |  |
| Good return on equity | failed | 8.5% |  |
| Debt under control | passed | 0.01 |  |
| Turns sales into cash | passed | 12.9% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $830.8M |
| Net income, trailing twelve months | $55.2M |
| Free cash flow, trailing twelve months | $106.9M |
| Net margin | 6.6% |
| Operating margin | 0.8% |
| Return on equity | 8.5% |
| Debt to equity | 0.01 |
| Diluted EPS, trailing twelve months | $0.42 |
| Share price | $116.10 |
| Market value | $12.6B |
| Price / earnings | 276.4x |
| Price / sales | 15.1x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/cort)
- [Financial statements](https://inspectstocks.com/stocks/cort/financials)
- [Competitors](https://inspectstocks.com/stocks/cort/peers)
- [Earnings](https://inspectstocks.com/stocks/cort/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.